TLSI: מחיר רכישת החברה TriSalus Corp

This chart illustrating the price evolution demonstrates an Enterprise Value of 222.12. TriSalus Life Sciences (TLSI) is developing methods to combat gastric tumors, creating synergy through partnerships with oncology centers in the field of drug delivery systems. The company combines engineering and medical expertise to save lives, while steady demand for infusion equipment ensures a consistent inflow of capital.

To stress-test assets, it is necessary to evaluate total capital, combining market capitalization and net debt, which allows for the determination of the actual business buyout cost. By analyzing the enterprise value, an investor can see to what extent the patent protection of TriSalus Life Sciences (TLSI) targeted drug delivery systems is capitalized into the company's overall valuation, accounting for its credit leverage and liquidity.